Judging by today’s news cycle, you might think that the world of IP is quite advanced when it comes to artificial intelligence .
Argentum Pharmaceuticals can’t have a Novartis patent for a multiple sclerosis drug invalidated because it doesn’t have standing to bring the challenge, the US Court of Appeals for the Federal Circuit has ruled.
Pfizer has been rebuked by judges for filing thin evidence in support of what the pharma company called its ‘self-evident’ standing to bring a patent challenge.
3M has convinced a US judge to grant a restraining order against a New Jersey company it has accused of infringing the 3M trademarks by reselling N95 masks at “grossly inflated” prices amid the COVID-19 pandemic.
Massachusetts-based pharmaceutical company Akebia has had five Fibrogen patents for an anaemia treatment invalidated at the English High Court.
NASCAR driver Caesar Bacarella’s sports clothing line and supplement business have been hit with a lawsuit by an Australia company.
The US Court of Appeals for the Federal Circuit has affirmed a lower court’s decision which found that Banner Life Sciences wasn’t infringing a Biogen patent with its bioequivalent version of a multiple sclerosis drug.
The COVID-19 pandemic is heightening the dangers posed by the global trade in counterfeit pharmaceutical products, according to the OECD and EUIPO.
A total of 79 vaccines and 155 drugs are currently being developed across the globe to combat COVID-19, according to statistics from the Austrian Institute for Health Technology Assessment.
The US Court of Appeals for the Federal Circuit has overturned a lower court’s decision to find a heart monitoring patent invalid under Alice, handing a win to medical laboratory company BioTelemetry.